glp-1 drugs brands Compound versions of for weight loss halted by FDA The ABC's of GLP-1s: Benefits,
Description
In 2024 the journal Diabetes named it as a classic paper
This marked a turning point, shifting GLP-1 agonists from diabetes-focused therapies to primary obesity treatments
These detrimental cells, known as senescent cells, stop serving their particular function and begin to spew detrimental molecules
Even a two to four week taper is significantly better than abrupt cessation
Trials are investigating whether these drugs can reduce risks of cardiovascular disease, fatty liver, and even dementia
L., Calanna S., et al
